Anti-PDGFR-beta antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-9650444-B2
Application number	US-201614992589-A
Country	US
Kind code	B2
Filing date	Jan 11, 2016
Priority date	Jan 9, 2013
Publication date	May 16, 2017
Grant date	May 16, 2017

Abstract

The present invention provides antibodies that bind to platelet derived growth factor receptor beta (PDGFR-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PDGFR-beta with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with PDGFR-beta signaling and/or PDGFR-beta cellular expression, such as ocular diseases, fibrotic diseases, vascular diseases and cancer.

First claim

What is claimed is:

1. A method of blocking monomeric human platelet derived growth factor receptor beta (PDGFR-beta) signaling in a subject, comprising:
administering to the subject a pharmaceutical composition comprising an isolated antibody or antigen-binding fragment thereof that specifically binds (PDGFR-beta) with a binding dissociation equilibrium constant (K D ) of less than about 30 nM as measured in a surface plasmon resonance assay at 37° C.;
wherein the isolated antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) comprising SEQ ID NOs: 132, 134 and 136, respectively; and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) comprising SEQ ID NOs: 140, 142 and 144, respectively.

2. The method of claim 1 , wherein the isolated antibody or antigen-binding fragment thereof specifically binds to monomeric PDGFR-beta with a K D of less than about 10 nM as measured in a surface plasmon resonance assay at 37° C.

3. The method of claim 1 , wherein the isolated antibody or antigen-binding fragment thereof specifically binds dimeric human platelet derived growth factor receptor beta (PDGFR-beta) with a binding dissociation equilibrium constant (K D ) of less than about 200 pM as measured in a surface plasmon resonance assay at 37° C.

4. The method of claim 1 , wherein the isolated antibody or antigen-binding fragment thereof blocks binding of at least one PDGF ligand to PDGFR-beta.

5. The method of claim 4 , wherein the isolated antibody or antigen-binding fragment thereof blocks PDGF-BB ligand binding to soluble monomeric PDGFR-beta with an IC 50 value of less than about 300 pM as measured in an in vitro receptor/ligand binding assay at 25° C.

6. The method of claim 5 , wherein the isolated antibody or antigen-binding fragment thereof inhibits PDGF ligand-mediated activation of PDGFR-beta signaling in cells that express PDGFR-beta.

7. The method of claim 1 , wherein the isolated antibody or antigen-binding fragment thereof specifically interacts with one or more amino acids within Ig domain 2 of the extracellular domain of PDGFR-beta (within amino acids 97 through 178 of SEQ ID NO:337).

8. The method of claim 1 , wherein the isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) comprising SEQ ID NO:130, and a light chain variable region (LCVR) comprising SEQ ID NO:138.

9. The method of claim 1 , wherein the pharmaceutical composition further comprises a VEGF antagonist and a pharmaceutically acceptable carrier or diluent wherein the VEGF antagonist is selected from the group consisting of aflibercept, bevacizumab, and ranibizumab.

10. A method of treating neovascular age-related macular degeneration (AMD) in a subject, comprising:
administering to the subject in need thereof a pharmaceutical composition comprising (i) an isolated antibody or antigen-binding fragment thereof that specifically binds monomeric human platelet derived growth factor receptor beta (PDGFR-beta) with a binding dissociation equilibrium constant (KD) of less than about 30 nM as measured in a surface plasmon resonance assay at 37° C., and (ii) a VEGF antagonist selected from the group consisting of aflibercept, bevacizumab, and ranibizumab,
wherein the isolated antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) comprising SEQ ID NOs: 132, 134 and 136, respectively; and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) comprising SEQ ID NOs: 140, 142 and 144, respectively;
thereby treating AMD in the subject.

11. The method of claim 10 , wherein the isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) comprising SEQ ID NO:130, and a light chain variable region (LCVR) comprising SEQ ID NO: 138.

12. The method of claim 10 , wherein the VEGF antagonist is aflibercept.

13. The method of claim 10 , wherein the isolated antibody or antigen-binding fragment thereof is administered to the subject prior to, concurrent with, or after administration of the VEGF antagonist to the subject.

14. The method of claim 10 , wherein the isolated antibody or antigen-binding fragment thereof and the VEGF antagonist are administered to the subject together in a single formulation.

15. The method of claim 10 , wherein the isolated antibody or antigen-binding fragment thereof and the VEGF antagonist are administered to the subject in separate dosage forms.

16. The method of claim 14 , wherein the isolated antibody is administered to the subject in a co-formulation with the VEGF antagonist, wherein the antibody or antigen-binding fragment is administered in an amount selected from the group consisting of 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg., 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5.0 mg and 5.5 mg, and wherein the VEGF antagonist is administered to the subject in an amount selected from the group consisting of 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2.0 mg, 2.1 mg, 2.2 mg, 2.3 mg, 2.4 mg, 2.5 mg, 2.6 mg, 2.7 mg, 2.8 mg, 2.9 mg and 3.0 mg.

17. The method of claim 16 , wherein the isolated antibody and the VEGF antagonist are administered in an amount selected from the group consisting of 0.2 mg anti-PDGFR-beta antibody and 2 mg aflibercept, 0.5 mg anti-PDGFR-beta antibody and 2 mg aflibercept, 1 mg anti-PDGFR-beta antibody and 2 mg aflibercept, 3 mg anti-PDGFR-beta antibody and 2 mg aflibercept, and 4 mg anti-PDGFR-beta antibody and 2 mg aflibercept.

Assignees

• Regeneron Pharma

Inventors

• Wiegand Stanley J
• Lobov Ivan B

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P27/06

  Antiglaucoma agents or miotics · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P27/00

  Drugs for disorders of the senses · CPC title